Nonnucleoside Reverse Transcriptase Inhibitor Therapy
Findings from Gilead Sciences, Inc. provide new insights into nonnucleoside reverse transcriptase inhibitor therapy
Published in AIDS Weekly, February 22nd, 2010
A new study, 'Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934,' is now available. According to recent research from the United States, "Study 934 was an open-label, randomized Phase III study of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine + efavirenz (3TC + ZDV + EFV) in antiretroviral therapy-naive HIV-1 infected subjects. Baseline genotyping revealed the presence of primary nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R) in 22 of 509 enrolled...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2010-02-22)
More Articles from AIDS Weekly
- Society for Research in Child Development
For HIV-infected children, quality of caregiver relationship is crucial - University of California - San Diego
Burden of HIV/TB infections increasingly falling on Hispanic community - Acute Hepatitis
Research results from University of New South Wales update understanding of acute hepatitis - Cancer Vaccines
Researchers at National Autonomous University have published new data on cancer vaccines - Cardiovascular Disease
Reports summarize cardiovascular disease research from University of Minnesota - Dentistry
Study results from S. Barber and colleagues broaden understanding of dentistry - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
